Clotting Factor VIII Biosimilar C018 Syd Labs | Ushelf
Clotting Factor VIII Biosimilar C018 Syd Labs | Ushelf

Clotting Factor VIII Biosimilar | C018

BeneFIX Biosimilar, Recombinant Coagulation Factor IX C019P Syd Labs | Ushelf BeneFIX Biosimilar, Recombinant Coagulation Factor IX | C019P
Clotting Factor VIII Biosimilar C018 Syd Labs | Ushelf

Clotting Factor VIII Biosimilar | C018

In stock
Catalog No.: C018 | In Vivo Grade

Advate / Kogenate biosimilar CHO stable cell line is available for licensing to manufacture the clotting factor VIII biosimilar protein.

The research grade clotting factor VIII biosimilar protein is for research use only.

This product is currently out of stock and unavailable.

Catalog No. C018
Product Name Advate / Kogenate Biosimilar Stable Cell Line
Supplier Name Syd Labs, Inc.
Brand Name Syd Labs
Applications Functional assays
Form Of Antibody 0.2 uM filtered solution, no stabilizers or preservatives
Endotoxin < 0.1 EU per 1 ug of the protein by the LAL method
Purity >95% by SDS-PAGE under reducing conditions and HPLC
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied
Note Advate / Kogenate biosimilar CHO stable cell line is available for licensing to manufacture the clotting factor VIII biosimilar protein. The research grade clotting factor VIII biosimilar protein is for research use only.
Order Offline Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C018: Advate / Kogenate Biosimilar Stable Cell Line

The yield of Advate / Kogenate Biosimilar from the CHO stable cell line was above 60 IU/ml in a 50 liter manufacturing.

The Advate / Kogenate Biosimilar stable cell line alone can be transferred alone or together with the technology of process development and/or antibody purification.

Advate / Kogenate is used to replace clotting factor VIII to prevent and control bleeding in adults and children (0-16 years) with hemophilia A. Haemophilia A, about 80% of haemophilia cases and present in about 1 in 5,000–10,000 male births, is a recessive X-linked genetic disorder and caused by deficiency in the functional clotting Factor VIII. Without the functional clotting Factor VIII, bodies of patients with Haemophilia A lose the control of normal blood clotting or coagulation, critical to stop bleeding when a blood vessel is broken.

Syd Labs also provides the following clotting or coagulation-related biosimilar stable cell lines:
ReFacto Biosimilar Stable Cell Line (truncated Factor VIII)
NovoSeven Biosimilar Stable Cell Line (Factor VIIa)
BeneFIX Biosimilar Stable Cell Line (Factor IX)

You may also like…